AuraVax Therapeutics Inc
Develops intranasal immune-based therapeutics and mucosal adjuvants that activate the STING pathway to boost innate immunity against multiple respiratory pathogens. The company advances a nanoparticle formulation to deliver a STING agonist (cGAMP) for prevention, treatment, and vaccine enhancement, and pursues academic licenses and government collaborations to support preclinical development.
Industries
Nr. of Employees
small (1-50)
Products
Intranasal host-directed therapeutic (STING agonist formulation) for prevention and treatment of respiratory infections
A nanoparticle formulation designed to deliver a STING pathway activator intranasally to boost innate immunity and reduce disease severity and transmission across multiple respiratory pathogens.
Intranasal mucosal vaccine adjuvant (STING agonist nanoparticle)
A liposomal STING agonist intended to enhance mucosal and systemic immune responses when combined with intranasal vaccines, with the goal of improving efficacy and reducing required antigen dose.
Next-generation intranasal host-directed therapeutic (development pipeline)
Ongoing development of subsequent host-directed therapeutic candidates applying the same STING-activation approach for improved efficacy and durability.
Intranasal host-directed therapeutic (STING agonist formulation) for prevention and treatment of respiratory infections
A nanoparticle formulation designed to deliver a STING pathway activator intranasally to boost innate immunity and reduce disease severity and transmission across multiple respiratory pathogens.
Intranasal mucosal vaccine adjuvant (STING agonist nanoparticle)
A liposomal STING agonist intended to enhance mucosal and systemic immune responses when combined with intranasal vaccines, with the goal of improving efficacy and reducing required antigen dose.
Next-generation intranasal host-directed therapeutic (development pipeline)
Ongoing development of subsequent host-directed therapeutic candidates applying the same STING-activation approach for improved efficacy and durability.
Services
Partnerships and licenses with academic institutions and government agencies to co-develop intranasal therapeutics and vaccine adjuvants.
Partnerships and licenses with academic institutions and government agencies to co-develop intranasal therapeutics and vaccine adjuvants.
Expertise Areas
- Host-directed therapeutics for respiratory disease
- Mucosal immunology and intranasal vaccine adjuvants
- Lipid nanoparticle formulation for airway delivery
- Preclinical respiratory infection and transmission models
Key Technologies
- STING pathway activation (cGAMP delivery)
- Liposomal / lipid nanoparticle delivery
- Intranasal (mucosal) drug delivery
- Mucosal adjuvant platforms
News & Updates
Article referencing an intranasal vaccine program associated with the company’s platform.
Preclinical publication describing intranasal vaccine protection and transmission prevention in animal models.
Preclinical publication reporting protection from respiratory viruses using an intranasal STING agonist in animal models.
Entered an exclusive license with an academic institution for intranasal vaccine and therapeutics technology.
Entered an exclusive license with an academic medical center for intranasal vaccine and therapeutics platform.
Received government contract funding to evaluate the intranasal platform as a mucosal adjuvant for pandemic influenza vaccine development.
Article referencing an intranasal vaccine program associated with the company’s platform.
Preclinical publication describing intranasal vaccine protection and transmission prevention in animal models.
Preclinical publication reporting protection from respiratory viruses using an intranasal STING agonist in animal models.
Entered an exclusive license with an academic institution for intranasal vaccine and therapeutics technology.
Entered an exclusive license with an academic medical center for intranasal vaccine and therapeutics platform.
Received government contract funding to evaluate the intranasal platform as a mucosal adjuvant for pandemic influenza vaccine development.